In ImmunoCellular’s follow-on Phase II trial of ICT-107, there are 213 patients enrolled to date, of which 100 patients have been either randomized (or treated with the product) or are waiting to complete radiation therapy prior to treatment. The Company recently announced that its Phase II trial is now on-going at 25 sites, with patients enrolled in leading medical centers such as Mass General Cancer Center and the Dana Farber Cancer Institute. ImmunoCellular plans to continue enrollment for a short time to ensure enough patients will be available for the data analysis. The trial, as originally designed, was to enroll over 200 patients to treat at least 102 patients with HLA-A1/A2 immunological subtypes.“The continued impressive survival data we have seen to date and the timely enrollment in our ongoing Phase II trial, further build our confidence that targeting CSCs may provide a breakthrough in the treatment of GBM,” said Manish Singh, Ph.D., President and CEO of ImmunoCellular. “As we complete enrollment of our Phase II trial, we look forward to obtaining patient data.”
ImmunoCellular Therapeutics To Present Long-term Survival Data From Clinical Study Of ICT-107 In Glioblastoma Multiforme At American Society Of Clinical Oncology Meeting
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.